The FDA authorizes bamlanivimab, by Eli Lilly, for patients with mild-to-moderate COVID-19. According to the FDA:
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.
The FDA also issued an emergency use authorization for REGN-COV2 (REGN10933 and REGN10987), by Regeneron. For more information on these treatments, listen to NPR “Short Wave.”